Regent Pacific Group Limited Overview
| Metric | FY2023 | FY2024 | H1 2025 |
|---|---|---|---|
| Employees (headcount, group excl. associate) | — | 17 | 17 |
| Consultants | — | 2 | 1 |
The 30 June 2024 and 30 June 2025 figures are the disclosed data points.
Regent Pacific is a micro-cap Hong Kong-listed holding company that has evolved from a 1990s emerging-markets fund manager and resources investor into a two-asset life-sciences platform.
The first asset is Plethora Solutions, the UK owner of Fortacin™/Senstend™. This is a topical lidocaine/prilocaine spray for premature ejaculation (PE). It is out-licensed to:
-
Recordati in Europe;
-
Jiangsu Wanbang Biopharmaceutical (a Fosun Pharma subsidiary) in China, where NMPA approval was granted on 16 June 2026;
-
Kobayashi Pharmaceutical in Japan.
The second asset is Deep Longevity, an AI "aging clock" software business (BloodAge, MindAge, BiometricAge, EpigeneticAge). It is now pivoting into US direct-to-consumer telehealth through Accrua™, launching in October 2026.
The group is capital-light but cash-constrained. It has had net liabilities since 2023, depends on loans from Galloway (a vehicle associated with controlling shareholder Jim Mellon), and carries a going-concern material uncertainty. The investment case is now a binary bet on Senstend™ China royalties (low-to-mid-teens royalties plus up to US$25M in sales milestones) and on Accrua's consumer traction.
Company's own description (Interim Report 2025, note 1 and note 4)
The company describes itself as "engaged in investment holding" with principal activities consisting of "investments in biopharma companies and other corporate investments." It reports two operating segments:
Biopharma: research, development, manufacturing, marketing and sale of pharmaceutical products, and development of AI systems for biological aging clocks.
Corporate Investment: investment in listed and unlisted corporate entities.
The Accrua press release (28 Sep 2026) describes Regent Pacific as "a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors." It states the group has returned approximately US$298 million to shareholders since its IPO in May 1997.
Independent characterisation
Functionally, Regent Pacific is a royalty-and-milestone licensor plus an early-stage SaaS business, run from a small Hong Kong head office with a UK pharma subsidiary and a US/global AI subsidiary. It does not manufacture, distribute or hold drug inventory.
Plethora (Fortacin™/Senstend™):
-
Value creation comes through out-licensing to regional pharma partners: Recordati (Europe), Wanbang/Fosun (China), Kobayashi (Japan), and South-East Asian licensees.
-
Partners fund registration and commercialisation; Plethora receives upfront and milestone payments plus royalties.
-
Manufacturing is contracted to third parties. Genetic S.p.A. signed a manufacturing and supply agreement to supply Senstend™ to Wanbang (announced after 30 Jun 2024). A "new manufacturer" is being qualified for South-East Asia.
-
The US is the largest unpartnered market. It requires a further Phase 3 study ("Study 008"), which management seeks to fund through an out-licence.
Deep Longevity (DLI):
-
Monetises proprietary deep-learning aging clocks through B2B SaaS (the SenoClock® platform) and per-report sales (AgeMetric™ / BloodAge© / MindAge© reports).
-
Customers are longevity clinics, laboratories, insurers and wellness platforms.
-
From October 2026, it adds a direct-to-consumer telehealth model (Accrua™). This model is expected to be largely subscription-based and recurring. Clinical delivery is outsourced to US telehealth infrastructure, physician and compounding-pharmacy partners.
Corporate Investment: This is now a residual. It held listed equities in Canadian and Australian dollars worth about US$2k and an unlisted HK club debenture worth about US$19k at 30 Jun 2025. It is also the cost centre carrying head-office G&A.
Revenue model mix (H1 2025, the latest pre-milestone period with full disclosure)
| Revenue stream | H1 2024 (USD K) | H1 2025 (USD K) | Model type |
|---|---|---|---|
| Royalty income (Fortacin™, mainly Recordati) | 80 | 149 | Licensing / royalty |
| Deep Longevity subscription and support | 43 | 87 | Subscription (SaaS) |
| Biological age reports | 0 | 1 | Transactional |
| Total revenue | 123 | 237 | — |
Source: Interim Report 2025, note 4.
In H1 2026, the mix shifted dramatically. The group recognised a net US$4.5M milestone (the US$5M NMPA approval milestone less PRC withholding tax) as revenue, per the positive profit alert of 3 Aug 2026. Licensing therefore represented more than 90% of H1 2026 revenue (derived).
Customer types and end-markets
| Business | Customer type | End-market |
|---|---|---|
| Fortacin™ (EU) | Recordati, which sells to pharmacies and prescribers | Men's sexual health; leading markets Italy, Germany, France, Portugal |
| Senstend™ (China) | Jiangsu Wanbang Biopharmaceutical (wholly controlled by Shanghai Fosun Pharmaceutical) | Chinese PE market; first commercial sale expected H2 2026 |
| Fortacin™ (Japan) | Kobayashi Pharmaceutical Co., Ltd. | Japan; clinical studies targeted to begin 2026 |
| Fortacin™ (South-East Asia) | Regional licensees (names not disclosed in reviewed documents) | Selected South-East Asian countries |
| Deep Longevity B2B | Longevity clinics, labs, insurers, wellness platforms (e.g. Humansa Health, HK; Holistica World, India) | Longevity/wellness diagnostics |
| Accrua™ (D2C) | US consumers in all 50 states | US consumer telehealth: GLP-1 weight loss, peptides, HRT, testosterone |
Strategy
Stated strategy themes (Interim Report 2025, Strategic Plan and Outlook)
The company states it will:
-
Pursue commercialisation of Fortacin™/Senstend™ in the remaining key markets: China, the US, South-East Asia, Japan, Latin America and the Middle East.
-
Commercialise deep-learning aging clocks and MindAge©, partnering with clinics, laboratories and insurers through AgeMetric™ reports and SaaS access.
-
Continue strategic, value-led investments in healthcare and life sciences.
The Strategic Plan commits to:
-
divestment of non-core assets;
-
use of international and local expertise to tackle difficult markets;
-
use of the Hong Kong listing for liquidity and capital access while maintaining governance standards.
It also aims to return surplus capital through an effective dividend policy and share repurchases. This aim is aspirational given the capital deficiency.
Initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Senstend™ China NDA and approval | Dec 2024 → 16 Jun 2026 | NDA filed; first-stage review passed 24 Mar 2025; approved Jun 2026 | Achieved |
| Senstend™ first commercial sale | H2 2026 (guided) | Triggers US$2M milestone | Pending |
| Fortacin™ US Phase 3 and out-licensing | 2025–2026 | Two CRO proposals evaluated; licensing talks targeted for end-2025 | Not yet announced |
| Kobayashi Japan clinical programme | 2,026 | Kobayashi to begin clinical studies | In progress |
| South-East Asia supply transfer | 2025–2026 | New manufacturer variations | In progress |
| Deep Longevity US expansion | Q1 2026 | US sales team from 1 Jan 2026; CCO and VP Sales hired; target of 50+ US clients (exact target wording truncated in source) | In progress |
| Deep Longevity product R&D | 2025–2026 | BiometricAge update; LLM upgrades; FaceAge in development | In progress |
| Accrua™ D2C telehealth | Announced 28 Sep 2026; launch Oct 2026 | GLP-1, peptides, HRT, testosterone; subscription model; partner-delivered | Launching |
| Balance-sheet repair | Apr–Jun 2025 | US$3.96M loan capitalisation; US$5M Galloway facility | Completed / ongoing |
ESG commitments: No quantified targets. An ESG report is included in the annual report per HKEX rules.
Cost programmes: Cost control measures are referenced in the going-concern basis. No numeric targets.
Medium-term financial targets: None published. There is no formal revenue or EBITDA guidance beyond milestone timing.
Products & Services
Biopharma: Plethora
| Product | Description | Key specifications | Target customer | Status / latest year | Commercial model | Flagship |
|---|---|---|---|---|---|---|
| Fortacin™ (EU/UK and other territories) | Topical metered-dose spray for premature ejaculation | Proprietary formulation of lidocaine plus prilocaine (two marketed local anaesthetics); acts peripherally, not on the CNS | Men with lifelong PE, via prescribers and pharmacies | EU approval c.2013; UK launch 2016; Recordati commercialising with uninterrupted supply (2025) | Out-licence to Recordati; royalties (US$149k in H1 2025) | Yes |
| Senstend™ (China) | Same product, branded for China | Import licence (NDA) granted by NMPA on 16 Jun 2026; 4-year data protection | Chinese PE patients via Wanbang/Fosun | Approved Jun 2026; first commercial sale expected H2 2026 | US$5M approval milestone (received/recognised); US$2M on first sale; up to US$25M sales milestones; tiered low-to-mid-teens royalties, subject to generic-entry adjustment | Yes |
| Fortacin™ (US) | Same product | Requires further Phase 3 ("Study 008"); two CRO proposals evaluated | US PE market | Pre-Phase 3; out-licensing discussions ongoing (targeted by end-2025, not yet announced as of review) | Seeking licensee to fund Phase 3 | Pipeline |
| Fortacin™ (Japan) | Same product | Kobayashi progressing regulatory pathway | Japanese market | Clinical studies targeted to begin 2026 | Out-licence to Kobayashi Pharmaceutical | Pipeline |
| Fortacin™ (South-East Asia) | Same product | Licensees negotiating regulatory variations and supply terms with a new manufacturer | Selected South-East Asian countries | Supply transition ongoing (2025) | Out-licence (licensee names not disclosed) | — |
Pricing: Not publicly disclosed by Regent Pacific or its licensees in the reviewed documents.
Market sizing claim: The 2024 Annual Report states an expectation of approximately 9 million patients in China in Senstend™'s first year, growing to over 170 million by year 10. This is company guidance and should be treated as aspirational.
Biopharma: Deep Longevity
| Offering | Description | Capabilities | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
| SenoClock® platform | SaaS platform hosting all aging clocks and longevity recommendations | Integrates multiple deep biomarkers of aging; "Longevity as a Service" | Clinics, labs, insurers, enterprises | Ongoing; LLM updated 2024–2025 | Subscription and support (US$87k in H1 2025) |
| BloodAge© | Deep-learning biological age from routine blood tests | Peer-reviewed: about 2,600 adults followed for a mean 9.2 years; each extra year of age gap associated with 15% higher mortality risk (Goshen et al., Aging and Disease, 2026) | B2B and, from Oct 2026, D2C via Accrua | Updated continuously | Per report / subscription |
| MindAge© | Psychological/cognitive aging clock | LLM-generated reports | B2B | Ongoing | Per report / subscription |
| BiometricAge | Biometric aging clock | Uses 17 additional blood biomarkers plus 4 biometric measures (including blood pressure and waist circumference) | B2B | Updated 2025 | Per report / subscription |
| EpigeneticAge | Epigenetic aging clock | Methylation-based | B2B | Listed in 2025–2026 releases | — |
| FaceAge / Face Index Score | Facial-image aging clock | In R&D | Health, beauty and wellness | "Upcoming" (2025–2026) | — |
| AgeMetric™ reports | Packaged biological-age reports | Report outputs from clocks | Clinics, insurers | Ongoing | Per report |
| Accrua™ | US D2C telehealth platform anchored to quarterly BloodAge measurement | Clinician-guided treatment: GLP-1 weight-loss medications, peptides, women's health (HRT), men's health (testosterone); HIPAA-compliant; LegitScript certification ahead of launch; all 50 states | US consumers | Launch October 2026 | Largely subscription-based, recurring |
Financial Narrative
Data hierarchy:
-
Company trading record (Interim Report 2025, p.57) for FY2021–FY2024.
-
S&P Global Market Intelligence (via StockAnalysis.com) for FY2025 and standardised lines.
-
Where the two differ, both are shown.
-
All figures are in US$ millions unless stated.
Income statement
Notes:
-
FY2025 finance costs are from S&P (US$0.37M). The company's FY2025 figure was not directly verified.
-
FY2025 net income is from S&P. FY2021–FY2024 net income is from the company trading record.
-
FY2021 net income benefited from about US$13.6M of gains on investment sales (S&P).
Margins
Revenue CAGR FY2021–FY2025: about -42% a year on S&P operating revenue (derived: 0.36/3.25 over 4 years). This figure is distorted by the FY2021 base, which included licence income.
Half-year bridge to the latest period
H1 2026 basis:
Revenue of about 5.28 is derived: from S&P TTM revenue of US$5.40M at Jun 2026 (5.40 − 0.36 + 0.24).
Net profit of about 0.55 is derived: from S&P TTM net income of −1.95 (−1.95 + 4.71 − 2.22). This sits inside the company's 3 Aug 2026 profit-alert range of US$0.5–1.0M.
-
The profit alert attributes the turnaround mainly to recognising a net US$4.5M milestone as revenue.
-
S&P also shows TTM income tax of about US$0.5M (consistent with PRC withholding tax) and TTM asset writedowns of about US$1.03M.
Balance sheet
Latest disclosed balance sheet (30 Jun 2025, Interim Report 2025):
-
Total assets: US$734k.
-
Cash: US$126k.
-
Trade receivables: US$220k.
-
Total liabilities: US$4.903M. These comprise payables and accruals of US$3.134M, shareholder loans of US$1.24M, lease liabilities of US$521k, and bank borrowing of US$8k.
-
Net current liabilities: US$4.146M.
-
Capital deficiency: US$4.169M.
It is likely more negative than −US$4.17M given the H2 2025 loss of about US$2.5M (derived) unless further capitalisations occurred.
Net debt: At 30 Jun 2025, net debt was about US$1.64M (derived: shareholder loans 1.24 + bank 0.008 + leases 0.52 − cash 0.126). Leases are included.
Cash flow
Disclosed half-year cash flows:
-
H1 2025 operating cash outflow: US$2.161M (H1 2024: US$2.555M).
-
H1 2025 capex: US$14k (computer equipment).
-
H1 2025 shareholder loan drawdowns: US$2.48M (H1 2024: US$0.72M).
-
H1 2024 included US$217k proceeds from investment disposals.
Ratios
Ratio notes:
ROE: is not meaningful because equity is negative. A vendor (Wisesheets) reports a TTM ROE of 87%, which is an artefact of a loss divided by negative equity.
Current ratio: for FY2024 is derived (601 / 5,649).
Interest coverage: is derived from S&P EBIT and company finance costs.
- ROA, ROIC, debt/equity, net debt/EBITDA, asset turnover and cash conversion cycle are not meaningful (negative equity and negative EBITDA) or not disclosed.
Commentary on trends, inflections and drivers
Three distinct financial regimes.
FY2021–FY2023: Large accounting losses: Losses of US$12.6M–36.4M a year were dominated by non-cash amortisation of the Fortacin™ intangible (about US$22–25M a year). FY2021 was flattered by about US$13.6M of investment gains, and FY2022 was hit by about US$4.1M of investment losses. Underlying cash burn (S&P EBITDA) was a steady US$5–6M a year.
FY2024–FY2025: Lean cash-burn shell: With the patent fully amortised on 19 Nov 2023, reported losses collapsed to about US$4.5–4.7M. This roughly equals G&A plus R&D less small royalty and SaaS income. Cash fell from US$2.10M (FY2023) to about US$0.1M (FY2024–FY2025). The group was funded by Galloway shareholder loans at 8–12%, which pushed finance costs up (to US$0.37M in FY2025 per S&P). Equity turned negative at FY2023 (−US$1.55M) and reached −US$5.90M by FY2024. The June 2025 debt-for-equity swap (US$3.96M) only partially repaired this.
H1 2026: Milestone-driven inflection: The NMPA approval of Senstend™ converted a US$5M contingent milestone into revenue (US$4.5M net of withholding). This produced the first half-year profit in the reviewed history (US$0.5–1.0M guided; about US$0.55M implied by S&P TTM data).
The key analytical point is that the recurring run-rate is still loss-making. H1 2025 recurring revenue was US$237k against about US$2.25M of operating and R&D costs. Sustainable profitability therefore depends on Senstend™ royalties scaling from H2 2026 and on Accrua™ achieving consumer traction.
Going concern. Every period reviewed carries a material uncertainty. In the 2025 interim, directors relied on the US$5M Galloway facility (12%, 12-month term from 20 Mar 2025) and cost controls, with a cash-flow forecast through 30 Sep 2026. The receipt of the US$5M milestone in H2 2026 should materially ease this pressure. Confirmation should be sought in the 2026 interim report.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Entity / Unit Details
| Entity / unit | Function | Ownership | Location |
|---|---|---|---|
Regent Pacific Group Limited | Listed holding company, head office, Corporate Investment segment | Listed | Cayman (incorporated) / Hong Kong (HQ) |
Plethora Solutions (Plethora Solutions Holdings and subsidiaries) | Fortacin™/Senstend™ IP owner and licensor | 100% (wholly-owned UK subsidiary) | United Kingdom (London historically) |
Deep Longevity, Inc. and subsidiaries | AI aging clocks, SenoClock® SaaS, Accrua™ D2C | 100% (acquired 2020) | Global; US commercial team from 1 Jan 2026 |
Associate (unnamed) | Carrying value US$1k | Associate | — |
Segment revenue (USD K)
| Segment revenue (USD K) | H1 2024 | H1 2025 |
|---|---|---|
Biopharma | 123 | 237 |
Corporate Investment | 0 | 0 |
Total | 123 | 237 |
Results by Segment
| Segment result (USD K) | H1 2024 | H1 2025 |
|---|---|---|
Biopharma segment loss | -655 | -325 |
Corporate Investment segment loss | -1,902 | -1,683 |
Total segment loss (loss from operations) | -2,557 | -2,008 |
Finance costs | -64 | -207 |
Loss before tax | -2,621 | -2,215 |
Segment Assets & Liabilities
| Segment balance (USD K) | FY2024 (31 Dec) | H1 2025 (30 Jun) |
|---|---|---|
Biopharma segment assets | 278 | 353 |
Corporate Investment segment assets | 331 | 380 |
Biopharma segment liabilities | 208 | 241 |
Corporate Investment segment liabilities | 2,976 | 2,901 |
Segment revenue (USD Mn)
| Segment revenue (USD Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Biopharma | 0.29 | 0.72 | 0.36 |
Corporate Investment | 0 | 0 | 0 |
Revenue by Segment
| Plethora (GBP K) | H1 2024 | H1 2025 |
|---|---|---|
Royalty income | 63 | 115 |
R&D (US FDA / Phase 3 related) | -144 | -70 |
G&A | -129 | -124 |
Operating loss | -210 | -79 |
Cash at period end | — | 23 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue, S&P operating revenue (USD Mn) | 3.25 | 0.11 | 0.29 | 0.72 | 0.36 |
Total revenue plus FV gain/(loss), company trading record (USD Mn) | 18.24 | -4.02 | 0.54 | 0.66 | 0.35 |
Gross profit, S&P (USD Mn) | 0.85 | -1.11 | -1.09 | -0.22 | -0.42 |
Operating income, S&P (USD Mn) | -28.77 | -30.77 | -27.95 | -4.19 | -4.30 |
Amortisation of intangibles (USD Mn) | 23.76 | 24.95 | 22.18 | 0 | 0 |
EBITDA, S&P (USD Mn) | -4.98 | -5.81 | -5.75 | -4.18 | -4.29 |
Finance costs, company (USD Mn) | 1.22 | 1.01 | 0.08 | 0.17 | 0.37 |
Pre-tax income (USD Mn) | -15.09 | -36.01 | -30.46 | -4.51 | -4.71 |
Income tax credit/(expense) (USD Mn) | 2.49 | -0.42 | 5.41 | 0.03 | 0 |
Net income attributable (USD Mn) | -12.60 | -36.43 | -25.05 | -4.48 | -4.71 |
EPS basic, S&P (USD) | -0.11 | -0.30 | -0.11 | -0.02 | -0.02 |
EPS diluted, S&P (USD) | -0.11 | -0.30 | -0.11 | -0.02 | -0.02 |
Dividends per share (USD) | 0 | 0 | 0 | 0 | 0 |
Weighted shares, S&P (M, post-consolidation basis) | 120 | 120 | 225 | 228 | 261 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, S&P (%) | 26.1 | — | — | -30.5 | -115.7 |
Operating margin, S&P (%) | -884 | -26,995 | -9,605 | -583 | -1,184 |
Net margin, S&P (%) | -387 | -31,954 | -8,608 | -623 | -1,298 |
EBITDA margin, S&P (%) | -153 | — | — | — | — |
Income Statement
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Revenue (USD Mn) | 0.12 | 0.24 | 5.28 |
R&D expenditure (USD Mn) | 0.53 | 0.38 | — |
G&A expenditure (USD Mn) | 2.01 | 1.87 | — |
Finance costs (USD Mn) | 0.06 | 0.21 | — |
Net profit/(loss) (USD Mn) | -2.62 | -2.22 | 0.55 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (USD Mn) | — | — | — | 0.61 | — |
Total current assets, S&P (USD Mn) | 12.79 | 2.31 | 2.79 | 0.60 | 0.56 |
Cash and equivalents (USD Mn) | 0.61 | 0.31 | 2.10 | 0.10 | 0.14 |
Trading securities (USD Mn) | 10.51 | 1.10 | 0.32 | 0.02 | 0.02 |
Shareholder loans (USD Mn) | — | — | 0 | 2.57 | — |
Bank borrowings, UK Bounce Back Loan (USD Mn) | — | — | — | 0.011 | — |
Lease liabilities (USD Mn) | — | — | — | 0.76 | — |
Total equity / (capital deficiency) (USD Mn) | — | — | -1.55 | -5.90 | — |
Goodwill and intangibles (USD Mn) | — | — | 0 | 0 | 0 |
Working capital (USD Mn) | — | — | — | -5.05 | — |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Free cash flow, S&P (USD Mn) | -1.75 | 0.49 | -3.81 | -4.13 | -4.31 |
Dividends paid (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (USD Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | — | — | n/m | n/m | n/m |
Current ratio (x) | — | — | — | 0.11 | — |
Interest coverage, EBIT/interest (x) | -23.6 | -30.5 | -349 | -24.6 | -11.6 |
Region revenue (USD K)
| Region revenue (USD K) | H1 2024 | H1 2025 |
|---|---|---|
Europe | 86 | 169 |
United States | 12 | 4 |
Middle East | 0 | 8 |
Asia Pacific | 25 | 56 |
Total | 123 | 237 |
Region Overview
| Region | YoY growth (%) |
|---|---|
Europe | 96.5 |
United States | -66.7 |
Middle East Details
| Middle East | n/m (from zero) |
|---|---|
Asia Pacific | 124.0 |
Share Price History
| Date | Price (HKD) | Source |
|---|---|---|
19 May 1997 (IPO) | 2.62 | etnet |
22 Nov 2024 | 0.40 | etnet |
18 Dec 2024 | 0.33 | MT Newswires |
7 Apr 2025 | 0.485 | Interim Report 2025 (capitalisation price) |
Apr 2026 (approx.) | 0.61 | etnet quote page |
30 Jul 2026 | 0.92 | StockAnalysis.com |
9 Oct 2026 | 0.875 | StockAnalysis.com |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | about US$32.7M | 291.8M shares × HK$0.875 ÷ 7.80 |
EV | about US$34M | Market cap plus about US$1.6M net debt (Jun 2025 basis; stale) |
EV / Sales (TTM Jun 2026) | about 6.3x | TTM revenue US$5.4M (milestone-inflated) |
EV / Sales (FY2025) | about 94x | Revenue US$0.36M |
P/E | n/m | TTM loss (−US$1.95M) |
EV / EBITDA | n/m | TTM EBITDA about US$0.14M (milestone-driven) |
P/B | n/m | Negative equity |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None; no sell-side coverage identified |
Dividend history and policy | No dividends in FY2020–FY2025 or H1 2026. Policy: return surplus capital via "an effective dividend policy and share repurchase programme" (aspirational). About US$298M returned to shareholders since the 1997 IPO. |
Buybacks | General repurchase mandate approved at the 19 Jun 2025 AGM; no repurchases disclosed |
Credit ratings | None (Moody's / S&P / Fitch: not rated) |
Debt maturity profile | Galloway facility: 12-month term from 20 Mar 2025, extendable by mutual consent (US$1.24M drawn at 30 Jun 2025). UK Bounce Back Loan: fully repaid by May 2026 (US$8k outstanding at Jun 2025). Leases: US$479k current, US$42k non-current. |
Analyst Conclusions
Management guidance
There is no numeric earnings guidance. Stated milestones are:
-
first commercial sale of Senstend™ in China in H2 2026, triggering a US$2M milestone;
-
US Fortacin™ Phase 3 start and out-licensing;
-
Kobayashi Japan clinical studies in 2026;
-
Deep Longevity's US scale-up and Accrua™ launch in October 2026.
There is no consensus, as no analysts cover the stock.
Bull case
-
China royalty annuity. Senstend™ is approved and partnered with Fosun's Wanbang. Low-to-mid-teens royalties plus up to US$25M in sales milestones could exceed the current US$33M market cap if Chinese uptake approaches even a fraction of management's patient projections.
-
Self-funding inflection. The net US$4.5M milestone produced H1 2026 profitability. The US$2M first-sale milestone and royalties could cover the roughly US$4–5M annual cost base, removing dilution risk.
-
Accrua™ optionality. A capital-light D2C model on partner infrastructure, anchored to validated BloodAge science, enters a market where peers have scaled to hundreds of millions of dollars of revenue quickly.
Bear case
-
Recurring economics remain sub-scale. H1 2025 recurring revenue was US$237k. Excluding the one-off milestone, the business still loses about US$4M a year, and equity was negative at the last verified date.
-
Short and fragile exclusivity. China protection is 4 years with generic adjustment, against entrenched cheap dapoxetine generics. The US programme has repeatedly missed out-licensing targets.
-
Controlled, illiquid micro-cap. Mellon interests hold about 57–66%, funding comes from a related party, and there is no analyst coverage. Telehealth entry is high-burn and regulatorily exposed, so it could absorb the milestone cash.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| Senstend™ first commercial sale in China and US$2M milestone | H2 2026 |
| 2026 interim report: confirmation of equity position, going-concern language, Galloway balance | Published Aug–Sep 2026 (verify) |
| Early Chinese prescription and royalty data | H1 2027 results (Mar 2027) |
| Accrua™ subscriber metrics and marketing spend | From Q4 2026 |
| US Fortacin™ out-licence announcement | Open-ended |
| Kobayashi Japan clinical trial initiation | 2026–2027 |
| Any equity issuance or new share scheme (2016 scheme expired) | Ongoing |
| Clarification of the PitchBook-listed "FZCO/CCEC" JV | Unconfirmed |
Concluding analyst verdict
Regent Pacific has spent a decade converting a legacy fund-management and resources vehicle into a narrowly focused life-sciences holding company. The June 2026 NMPA approval of Senstend™ is the first unambiguous proof that the Plethora licensing model can deliver.
The transaction structure is attractive. Fosun's Wanbang bears all Chinese commercialisation cost, while Regent Pacific collects milestones and low-to-mid-teens royalties on a product with a differentiated, non-systemic mechanism. The US$4.5M net milestone alone was roughly the group's full annual cash burn and delivered its first half-year profit in the reviewed history.
The equity story nevertheless remains high-risk. Before the milestone, the group operated with:
-
about US$0.1M of cash;
-
negative equity of US$4–6M;
-
a going-concern material uncertainty;
-
dependence on a lender associated with its controlling shareholder.
Recurring revenue (EU royalties plus Deep Longevity SaaS) is still well under US$1M a year. The longer-dated value drivers each carry significant execution risk: Chinese royalties face generics after four years of data protection, the US Fortacin™ programme has no partner, and Accrua™ is a late entrant to a crowded, heavily regulated telehealth market.
At about US$33M market capitalisation, the market is pricing a moderately successful China launch plus some Accrua™ optionality. That is reasonable but not obviously cheap, because the lack of disclosed royalty forecasts makes the China value hard to underwrite.
The decisive datapoints over the next 12 months are:
-
timing of the first Chinese sale;
-
the first reported royalty line;
-
whether management uses milestone cash to restore positive equity rather than fund aggressive US consumer marketing.
Until royalties are visible, the company is best viewed as a speculative, controlled micro-cap whose fundamental floor is set by Senstend™ economics and whose upside depends on management delivering partnering milestones that have historically slipped.
Confidence note: FY2025 and H1 2026 figures rely partly on S&P-standardised data and the company's profit alert. Final audited and interim statements should be checked for exact balance-sheet values.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / notes | Background |
|---|---|---|---|
James (Jim) Mellon | Non-Executive Chairman | Co-founder (1990); Chairman since 2002 | Oxford PPE (Masters, 1978); founder of Burnbrae, UraMin and Manx Financial; former Plethora chairman (2012–2016); controlling shareholder |
Jamie Alexander Gibson | Executive Director and CEO | — | Born 1966; drives licensing and Deep Longevity strategy |
Jayne Allison Sutcliffe | Non-Executive Director | Nomination Committee member from 30 Jun 2025 | Mellon associate (Charlemagne/Burnbrae group, per public records) |
Stawell Mark Searle | Independent Non-Executive Director | — | — |
Adrian Alan Chan Wan Tsun | Independent Non-Executive Director | Founded One Business Group (fractional C-suite platform) from 1 Jun 2025 | Former regional director, The CFO (HK) Ltd |
Ihsan Al Chalabi | Independent Non-Executive Director | Adjunct Professor, Biomedical Sciences, City University of Hong Kong (from 1 Jan 2025); Nomination Committee from 30 Jun 2025 | — |
Executive Leadership Team
| Name | Title | Born | Notes |
|---|---|---|---|
Dr Michael Grant Wyllie | Co-founder (Plethora) and Chief Scientific Officer | 1,951 | Urology pharmacologist |
Yui Fui Wong | Chief Financial Officer | 1,975 | — |
Paul Eric Jones | Investment Director | 1,965 | BA, MBA |
Lui Mei Yan (Winnie) | Company Secretary | 1,975 | — |
Prof John M. Fitzpatrick | Chairman, Clinical Scientific Advisory Board | — | Senior urologist |
Deepankar Nayak | CEO, Deep Longevity | — | Consultant via FOKI Limited (options granted 3 May 2023) |
Dylan Kay | Chief Commercial Officer (US), Deep Longevity | — | — |
Luke Shaffer | VP Sales (US), Deep Longevity | — | Appointed late 2025 |
Directors' Remuneration
| Name | Total pay (USD) | Basis |
|---|---|---|
Jamie Gibson | about 1.0–1.32M (vendor figures vary by currency conversion and year) | Yahoo Finance (latest annual report) |
Michael Wyllie | about 182–198k | Yahoo Finance |
Key management (aggregate) | 800k (H1 2025); 788k (H1 2024) | Interim Report 2025, note 19 |
Major Shareholders
| Holder | Shares | % | Date / basis |
|---|---|---|---|
James Mellon (direct and through associates) | 129,153,584 | 56.56 | 31 Dec 2023 (etnet) |
Galloway (lender; Mellon-associated vehicle per prior disclosures) | +63,377,163 capitalisation shares | — | Issued 25 Jun 2025 |
Mellon-concert group, pro forma | about 192.5M | about 66 | Derived (assumes Galloway is within the Mellon interest; verify against the latest SFO filings) |
Institutional ownership (top 10) | — | — | No meaningful institutional register disclosed |
Free float | about 34 | — | Derived |
Competitive Landscape
Key Competitors
| Competitor | Product | Positioning vs Fortacin™/Senstend™ |
|---|---|---|
A. Menarini (private) | Priligy® (dapoxetine, oral SSRI) | Systemic, on-demand oral; established in EU and Asia; CNS side-effect profile vs Fortacin's topical action |
Chinese dapoxetine generics (multiple domestic manufacturers) | Generic dapoxetine | Low-cost incumbents in China; key price competitors to Senstend™ |
Absorption Pharmaceuticals (Promescent) | OTC lidocaine spray (US) | OTC topical; competes in the US where Fortacin™ is unapproved |
Generic EMLA®-type lidocaine/prilocaine creams | Off-label topical anaesthetics | Cheap but messy; risk of partner transfer |
OTC benzocaine and lidocaine wipes and sprays (various brands) | Consumer products | Low-price substitutes |
Off-label daily SSRIs and tramadol (generic) | Systemic | Physician-prescribed alternatives |
Hims & Hers / Ro (telehealth) | Prescription PE regimens (e.g. sertraline, topical sprays) | Channel competitors in the US |
TruDiagnostic | Epigenetic age testing (TruAge) | Leading US epigenetic clock lab |
Tally Health | Consumer epigenetic test | D2C |
GlycanAge | Glycan-based biological age | Clinic channel |
Elysium Health | Index (epigenetic age) | Consumer |
InsideTracker | Blood-based "InnerAge" | Consumer/athlete |
Function Health | Broad blood panels | Large US consumer base |
Humanity / various apps | Wearable-based age scores | Free/low-cost |
Competitor Detail
| Metric | Regent Pacific |
|---|---|
Revenue (latest FY) | US$0.36M (FY2025, S&P) |
Growth | −50% (FY2025) |
Operating margin | −1,184% |
R&D intensity | about 161% of revenue (H1 2025) |



